These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 23875660

  • 1. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel.
    Arsov C, Winter C, Rabenalt R, Albers P.
    Urol Oncol; 2012 Mar; 30(6):762-71. PubMed ID: 20884252
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR, Hussain MH.
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [Abstract] [Full Text] [Related]

  • 8. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011 May; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

  • 9. Current state of castration-resistant prostate cancer.
    Petrylak DP.
    Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Recent advances in second-line treatment of castration-resistant prostate cancer.
    Ong M, Winquist E.
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
    [Abstract] [Full Text] [Related]

  • 12. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [Abstract] [Full Text] [Related]

  • 13. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F, Fizazi K.
    Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T, Shamseddine A.
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [Abstract] [Full Text] [Related]

  • 16. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
    Garcia JA, Rini BI.
    Cancer; 2012 May 15; 118(10):2583-93. PubMed ID: 22038761
    [Abstract] [Full Text] [Related]

  • 17. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
    Fernández O, Afonso J, Vázquez S, Campos B, Lázaro M, León L, Antón Aparicio LM.
    Anticancer Drugs; 2014 Mar 15; 25(3):237-43. PubMed ID: 24217332
    [Abstract] [Full Text] [Related]

  • 18. [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
    Akaza H.
    Nihon Rinsho; 2014 Dec 15; 72(12):2108-15. PubMed ID: 25518342
    [Abstract] [Full Text] [Related]

  • 19. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP.
    Can J Urol; 2014 Apr 15; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [Abstract] [Full Text] [Related]

  • 20. Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
    Harrington JA, Jones RJ.
    Eur J Cancer; 2011 Sep 15; 47(14):2133-42. PubMed ID: 21658937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.